供给：8 月，医药行业生产动能继续上升。8 月，医药行业工业增加值为 8.3%，增速较 7 月提高 0.9 个百分点。1～8 月，医药行业工业增加值为 6.9%，增速较 1～7 月提高 0.2 个百分点。需求：8 月，药品零售市场需求有所下降，中西药品零售总额环比下滑。8 月，中西药品零售总额为 476 亿元，环比下降 1.9%，同比增长 7.7%。1～8 月，中西药品零售总额为 3810.7 亿元，同比增长 10.6%，增速较 1～7 月下降 0.4 个百分点。

The global bone and joint health ingredients market (henceforth referred to as the market studied) is expected to reach USD 3,345.33 million by 2023, at an estimated CAGR of 6.3% over the forecast period (2018-2023). The market studied is segmented based on the type, application, and geography. Based on the type of bone and joint health ingredients, there are calcium, vitamin D, vitamin K, magnesium, collagen, glucosamine, and chondroitin, which are commercially relevant. Based on the application, the market is segmented into dietary supplement and functional food & beverage. The functional food & beverage segment has started emerging as a popular medium to consume bone and joint health promoting ingredients, particularly in the developed markets of Europe and North America.

The research process adopted for this study is a highly structured, two-stage process: size estimation of the review period and the market engineering for the forecast period, of the global-, country-, and segment-level data, which leads to the data generation process (DGP) for the studied variables. The size estimations are carried out through multiple bottom-up and top-down approaches. The bottom-up approach includes the examining of historical revenues of key players, studying the size of the applications, value and supply chain analysis, and end-user demand, which are then cross-validated against secondary and primary resources.

The report provides market dynamics and trends related to the global companion diagnostics market. In addition, it presents the market estimations and forecast of the market. The study estimates the revenue generated from the sales of companion diagnostics kits and does not include companion diagnostics service revenue. The valuations comprise revenue generated from companion diagnostics that are available for treatment of cancer, CNS disorders, infectious disease, and autoimmune disease. Furthermore, the report also excludes revenue generated from post-sale services of companion diagnostics. For the purpose of analysis, the global companion diagnostics market has been segmented based on technology type, indication, and region. The study estimates the revenue generated from the sales of companion diagnostic kits. On the basis of technology type, the market is categorized into immunohistochemistry, polymerase chain reaction (PCR), next generation sequencing (NGS), in situ hybridization, and others. Based on indication, the market is divided into oncology, neurology, and others. Oncology is further sub-segmented into lung cancer, colorectal cancer, breast cancer, blood cancer, and others. The report covers the revenue generated from the sales of products related to companion diagnostics systems offered in regions such as North America, Europe, Asia-Pacific, and LAMEA.

The term biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders. Biopharmaceutical products include (but are not limited to) monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzyme, synthetic immunomodulators, cell and gene therapies, and other products. The market estimation provided in the standard report is subject to the scope of the study, and may not be in line with the market estimates provided elsewhere.

Alzheimer's disease is a progressive, degenerative disorder that attacks the brain's nerve cells, or neurons, resulting in loss of memory, thinking, language skills, and behavioural changes. The market is anticipated to grow, driven by disease-modifying drugs, and the vast number of last-stage pipeline drugs. The market size provided in the report has been derived from the revenue generated by products and their distribution channel, considered in the scope of the report. For estimating the market size of the product, the average selling price (ASP) of a product in the region has been multiplied with the sales volume (new sales and replacement rate, based on the applicability).

Tuberculosis(TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it still remains one of the most common causes of death among adults, particularly in the emerging economies. The first line of treatment is mostly preferred and widely available across the world. However, with growing resistant to antibiotics, there is an increasing demand of innovative drug resistant TB medications to be widely available. These factors, along with others, drive the anti- tuberculosis therapeutics market.

Aesthetic threads are medical sutures that are injected using a needle underneath the skin, to lift and rejuvenate the skin. Suspension threads are one variety of long cosmetic threads that have cones or barbs, which pull backward on sagging skin, when injected with a needle into the target area on the face. Rejuvenation threads are another variety that have less of a lifting mechanism, but stimulate natural collagen production when injected underneath the skin. Market size provided in the report has been derived from the revenue generated by products. For estimating the market size of the product, the average selling price (ASP) of a product in the region has been multiplied with the sales volume (new sales and replacement rate, based on applicability).

As per the scope of the report, it covers kits, instruments, and consumables of the allergy in vitro tests, such as first-generation qualitative assays like (RAST), the second generation semi-quantitative IgE assays, and third-generation auto analyzers. Allergic diseases include anaphylaxis, food allergies, forms of asthma, conjunctivitis, eczema, eosinophilic disorders, and drug and insect allergies. Allergen-specific IgE antibody is the most common in vitro test for allergy and is used to diagnose type I hypersensitivity reactions to foods or reactivity to aeroallergens in patients.

截止 11月，科创板已受理企业达 175 家，其中医药生物公司占 42 席，分别为：微芯生物、南微医学、心脉医疗等。本系列我们接着介绍科创板中的医药生物企业——洁特生物。洁特生物的主营业务为生物实验室一次性耗材的研发、生产和销售。 

公司成立于 2005 年，主要生产动物源性植介入医疗器械系列化产品，覆盖外科软组织修复、先天性心脏病植介入治疗、心脏瓣膜置换与修复三大业务板块。公司产品一般应用于心胸外科手术、神经外科手术以及其他外科临床手术以替代或修复受损的组织或器官。

2017 年开始，医保收入增速有所回升，医保控费初见成效，医保结余率有所上升，后续医保支付将以结构调整为主。2019 新版医保目录落地，新增品种覆盖了要优先考虑的国家基本药物、癌症及罕见病等重大疾病治疗用药、慢性病用药、儿童用药等，药品结构进一步改善。同时，我国居民个人支付能力大幅提升，对创新药械等高端医疗需求强劲。在支付端改革以及需求的拉升下，创新药和器械将可以享受较强的定价权和估值的溢价，竞争优势明显。

我国现行的基本医疗保险制度体系由新中国时期的劳保医疗、公费医疗制度、传统农村合作医疗保险转变而来，现阶段共有城镇职工和城乡居民两种医保制度。城乡居民个人账户资金占比小，取消个人账户影响较小，逐步过渡为门诊统筹。

截至 2019 年 11 月 17 日，共有 160 家（除终止审查）企业向上海证券交易所申报科创板股票发行上市，其中 22 家医药制造企业、10 家医用设备制造企业、2 家研究和试验发展企业及 1 家橡胶和塑料制品业。在 35 家生物医药相关企业中，1 家近期确认受理，4 家由于财报过期等原因处于中止审核状态，1 家尚停留在问询未回复阶段，1 家暂缓审议，7 家已针对问询提交回复，2 家已通过审批，4 家提交注册，4 家注册生效，12 家已经发行。 

医药行业的收入与利润都保持增长势头，各细分领域增长幅度略有差异，估值还仍然低于近5年的均值水平，在A股市场国际化的背景下，行业越来越具有吸引力。 

2019 年09 月04 日，国家卫生健康委、财政部、国家中医药管理局联合印发《关于做好2019 年基本公共卫生服务项目工作的通知》（以下简称《通知》）指出，各地要在实施原基本公共卫生服务内容（12 类项目）的同时，对2019 年新划入的地方病防治、职业病防治、重大疾病及危害因素监测3 项重点工作按项目单列，明确资金和任务。2019 年人均基本公共卫生服务经费补助标准为69 元，新增5 元经费全部用于村和社区，要确保项目经费按时足额到位。

近年来社会整体经济水平的持续增长让国民公共卫生意识得到了较大程度的强化，同时社会各界在公共场所卫生方面的关注度也持续攀升，如何改善我国公共场所卫生监督监测质量已经发展成为一项重大的社会研讨课题。该文主要立足于我国公共场所卫生监督监测工作现状，对其存在的问题之处加以分析讨论，最后提出了一些改善对策，希望可以为相关人员提供有价值的参考，以促进我国公共场所卫生监督监测质量。

随着时代和社会发展速度的加快大大加快，了我国经济发展速度，同时进一步提升了人们的生活水平，在这样的背景下，我国汽车产业的发展速度也是非常快的。而随着汽车产业发展速度的加快，使国内环境和资源问题更加突出，这对人们的正常生活和工作造成了严重的不利影响。在这样的情况下新能源汽车应运而生，但是其在发展过程中是不顺利的。因此本文主要是对我国新能源汽车发展的现状、问题与对策方面进行了具体的研究与分析。